Do you want to read an article? Please log in or register.
AMPLIFY: Superior PFS with acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy in patients with treatment-naïve CLL
Leukemia
ASH 2024
Related content
EHA 2024
Leukemia
Zanubrutinib showed a significant PFS benefit versus acalabrutinib in patients with R/R CLL in a MAIC analysis
EHA 2024
Leukemia
Real-world study showed that initiating the next treatment was significantly more common among patients treated with first-line acalabrutinib versus first-line ibrutinib
SABCS 2024
Breast Cancer
PADMA: First-line palbociclib plus ET improves TFF and PFS versus chemotherapy in patients with high-risk HR-positive/HER2-negative metastatic breast cancer
Leukemia
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial
Lancet Oncol
Fürstenau M, Kater AP, Robrecht S, von Tresckow J, Zhang C, Gregor M, Thornton P, Staber PB, Tadmor T, Lindström V, Juliusson G, Janssens A, Levin MD, da Cunha-Bang C, Schneider C, Goldschmidt N, Vandenberghe E, Rossi D, Benz R, Nösslinger T, Heintel D, Poulsen CB, Christiansen I, Frederiksen H, Enggaard L, Posthuma EFM, Issa DE, Visser HPJ, Bellido M, Kutsch N, Dürig J, Stehle A, Vöhringer M, Böttcher S, Schulte C, Simon F, Fink AM, Fischer K, Holmes EE, Kreuzer KA, Ritgen M, Brüggemann M, Tausch E, Stilgenbauer S, Hallek M, Niemann CU, Eichhorst B
doi: 10.1016/S1470-2045(24)00196-7
EHA 2024
Multiple Myeloma (MM)
IMROZ: Frontline isatuximab plus VRd followed by isatuximab plus Rd shows significant PFS benefit and deep responses in patients with multiple myeloma
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Osimertinib plus local treatment for brain metastases versus osimertinib alone in patients with EGFR-Mutant Non-Small Cell Lung Cancer
★ 1
Recommended by
Dr Wolf-Dieter Janthur, Faculty Member
Lung Cancer
Tozuka T, Noro R, Mizutani H, Kurimoto F, Hakozaki T, Hisakane K, Naito T, Takahashi S, Taniuchi N, Yajima C, Hosomi Y, Hirose T, Minegishi Y, Okano T, Kamio K, Yamaguchi T, Seike M, East Japan Chesters Group
doi: 10.1016/j.lungcan.2024.107540
Leukemia
Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers
Am J Hematol
Abaza Y, Winer ES, Murthy GSG, Shallis RM, Matthews AH, Badar T, Geramita EM, Kota VK, Swaroop A, Doukas P, Bradshaw D, Helenowski IB, Liu Y, Zhang H, Im A, Litzow MR, Perl AE, Atallah E, Altman JK
doi: 10.1002/ajh.27231
Leukemia
Genetic Risk Stratification and Outcomes Among Treatment-Naive Patients With AML Treated With Venetoclax and Azacitidine
Blood
Döhner H, Pratz KW, DiNardo CD, Wei AH, Jonas BA, Pullarkat V, Thirman MJ, Récher C, Schuh AC, Babu S, Li X, Ku G, Liu Z, Sun Y, Potluri J, Dail M, Chyla B, Pollyea DA
doi: 10.1182/blood.2024024944
ESMO 2024
Breast Cancer